2019
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy
Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, Pohost GM, Sopko G, Chrzanowski L, Mark DB, Kukulski T, Favaloro LE, Maurer G, Farsky PS, Tan RS, Asch FM, Velazquez EJ, Rouleau JL, Lee KL, Bonow RO. Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy. New England Journal Of Medicine 2019, 381: 739-748. PMID: 31433921, PMCID: PMC6814246, DOI: 10.1056/nejmoa1807365.Peer-Reviewed Original ResearchMeSH KeywordsAgedCoronary Artery BypassEchocardiography, StressFemaleFollow-Up StudiesHeartHumansIncidenceKaplan-Meier EstimateMaleMiddle AgedMyocardial IschemiaProportional Hazards ModelsProspective StudiesStroke VolumeTomography, Emission-Computed, Single-PhotonTreatment OutcomeVentricular Function, LeftConceptsLeft ventricular ejection fractionVentricular ejection fractionMedical therapyEjection fractionMyocardial viabilityIschemic cardiomyopathyLeft ventricular systolic functionGoals of revascularizationCoronary artery bypassPrimary end pointVentricular systolic functionCoronary artery diseaseLeft ventricular functionLong-term outcomesLong-term survivalSurgical revascularizationDobutamine echocardiographyMedian durationSystolic functionArtery diseaseVentricular functionViable myocardiumLong-term benefitsLower incidenceCABG
2015
Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction
Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, LeWinter MM, Joseph SM, Shah SJ, Semigran MJ, Felker GM, Cole RT, Reeves GR, Tedford RJ, Tang WH, McNulty SE, Velazquez EJ, Shah MR, Braunwald E. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. New England Journal Of Medicine 2015, 373: 2314-2324. PMID: 26549714, PMCID: PMC4712067, DOI: 10.1056/nejmoa1510774.Peer-Reviewed Original ResearchConceptsHeart failureEjection fractionIsosorbide mononitratePlacebo groupDose regimensWalk distanceLife scoresN-terminal pro-brain natriuretic peptidePro-brain natriuretic peptideEnd pointSignificant between-group differencesIsosorbide mononitrate groupLow daily activityNT-proBNP levelsPrimary end pointSecondary end pointsSubmaximal exercise capacityDose-escalation regimenHours of activityActivity levelsBetween-group differencesDaily activity levelsDaily activitiesActivity toleranceExercise capacityOutcomes of Anatomical versus Functional Testing for Coronary Artery Disease
Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, Cole J, Dolor RJ, Fordyce CB, Huang M, Khan MA, Kosinski AS, Krucoff MW, Malhotra V, Picard MH, Udelson JE, Velazquez EJ, Yow E, Cooper LS, Lee KL. Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease. New England Journal Of Medicine 2015, 372: 1291-1300. PMID: 25773919, PMCID: PMC4473773, DOI: 10.1056/nejmoa1415516.Peer-Reviewed Original ResearchConceptsObstructive coronary artery diseaseCoronary artery diseaseCTA groupSymptomatic patientsArtery diseaseComposite primary end pointPrimary end-point eventEnd pointRadiation exposureInvasive cardiac catheterizationMajor procedural complicationsPrimary end pointSecondary end pointsEnd-point eventsCumulative radiation exposureMedian followChest painUnstable anginaCardiac catheterizationMore patientsProcedural complicationsClinical outcomesRandomized trialsAnatomical testingMean age
2014
Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction
Kukulski T, She L, Racine N, Gradinac S, Panza JA, Velazquez EJ, Chan K, Petrie MC, Lee KL, Pellikka PA, Romanov A, Biernat J, Rouleau JL, Batlle C, Rogowski J, Ferrazzi P, Zembala M, Oh JK, Investigators S. Implication of right ventricular dysfunction on long-term outcome in patients with ischemic cardiomyopathy undergoing coronary artery bypass grafting with or without surgical ventricular reconstruction. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 1312-1321. PMID: 25451487, PMCID: PMC4385741, DOI: 10.1016/j.jtcvs.2014.09.117.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiomyopathiesCoronary Artery BypassCoronary Artery DiseaseFemaleHeart VentriclesHumansKaplan-Meier EstimateMaleMiddle AgedPatient ReadmissionPlastic Surgery ProceduresProportional Hazards ModelsRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, RightVentricular Function, LeftVentricular Function, RightVentricular RemodelingConceptsRight ventricular dysfunctionCoronary artery bypassSurgical ventricular reconstructionSevere right ventricular dysfunctionArtery bypassVentricular dysfunctionRight ventricular functionVentricular reconstructionCause mortalityEnd pointVentricular functionClinical outcomesHigher pulmonary artery systolic pressureAdvanced left ventricular remodelingBaseline right ventricular functionPulmonary artery systolic pressureVentricular ejection fraction 35Ejection fraction 35Larger left ventriclePrimary end pointSecondary end pointsIschemic heart failureLow ejection fractionSevere mitral regurgitationCoronary artery diseasePROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial
Douglas PS, Hoffmann U, Lee KL, Mark DB, Al-Khalidi HR, Anstrom K, Dolor RJ, Kosinski A, Krucoff MW, Mudrick DW, Patel MR, Picard MH, Udelson JE, Velazquez EJ, Cooper L, investigators P. PROspective Multicenter Imaging Study for Evaluation of chest pain: Rationale and design of the PROMISE trial. American Heart Journal 2014, 167: 796-803.e1. PMID: 24890527, PMCID: PMC4044617, DOI: 10.1016/j.ahj.2014.03.003.Peer-Reviewed Original ResearchConceptsCoronary artery diseasePROMISE trialAnatomical testingProspective Multicenter Imaging StudyDiagnostic strategiesInitial diagnostic strategyMajor procedural complicationsSubsequent care decisionsComposite of deathPrimary end pointLarge pragmatic trialClinical care teamQuality of lifeDiagnostic testing strategiesMultidetector coronaryChest painSymptomatic patientsUnstable anginaArtery diseaseProcedural complicationsRandomized trialsSymptomatic subjectsClinical effectivenessMyocardial infarctionPragmatic trial
2013
Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction
Feldman AM, Mann DL, She L, Bristow MR, Maisel AS, McNamara DM, Walsh R, Lee DL, Wos S, Lang I, Wells G, Drazner MH, Schmedtje JF, Pauly DF, Sueta CA, Di Maio M, Kron IL, Velazquez EJ, Lee KL. Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. Circulation Heart Failure 2013, 6: 461-472. PMID: 23584092, PMCID: PMC3905743, DOI: 10.1161/circheartfailure.112.000185.Peer-Reviewed Original ResearchConceptsCoronary artery bypassPrimary end pointCoronary artery diseaseIndependent prognostic informationArtery bypassMultivariable analysisPrognostic informationSTNFR-1Artery diseaseClinical factorsPlasma levelsUnivariate analysisIschemic Heart Failure (STICH) trialEnd pointSoluble tumor necrosisHeart Failure TrialLeft ventricular reconstructionPrimary outcome variableNet reclassification improvementAbility of biomarkersSubstudy patientsVentricular dysfunctionCardiac hospitalizationBiomarker substudyHeart failureSystolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension
Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. The American Journal Of Medicine 2013, 126: 501-508. PMID: 23541376, DOI: 10.1016/j.amjmed.2013.01.007.Peer-Reviewed Original ResearchConceptsSystolic blood pressureHigh-risk hypertensive patientsPrimary end pointBlood pressure levelsSystolic bloodBlood pressureCardiovascular deathCardiovascular eventsCardiovascular outcomesCoronary eventsEnd pointHypertensive patientsMyocardial infarctionSystolic blood pressure levelsAvoiding Cardiovascular EventsSystolic Hypertension (ACCOMPLISH) trialTotal myocardial infarctionBlood pressure groupMajor cardiovascular eventsMean patient ageNonfatal myocardial infarctionCardiovascular event ratesRenal end pointsLower blood pressureTreatment of hypertensionEffect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor C, Felker GM, Goldsmith SR, Bart B, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial F. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2013, 309: 1268-1277. PMID: 23478662, PMCID: PMC3835156, DOI: 10.1001/jama.2013.2024.Peer-Reviewed Original ResearchConceptsPeak oxygen consumptionPhosphodiesterase-5 inhibitionExercise capacityWalk distanceEjection fractionHeart failureClinical statusPlacebo patientsAdverse eventsClinical trialsFilling pressureN-terminal brain-type natriuretic peptideElevated left ventricular filling pressureMedian peak oxygen consumptionPulmonary artery systolic pressureLeft ventricular filling pressureBrain-type natriuretic peptidePhosphodiesterase-5 inhibitor sildenafilEnd pointOxygen consumptionPrimary end pointSecondary end pointsVentricular filling pressureWeek 24 dataWeeks of therapy
2012
Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome
Bart B, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal Of Medicine 2012, 367: 2296-2304. PMID: 23131078, PMCID: PMC3690472, DOI: 10.1056/nejmoa1210357.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureDecompensated heart failureSerum creatinine levelsHeart failureUltrafiltration groupRenal functionCreatinine levelsPharmacologic therapyAdverse eventsEnd pointSafety of ultrafiltrationPrimary end pointSerious adverse eventsTreatment of patientsPersistent congestionDiuretic therapyCardiorenal syndromeRandomized trialsMean changePatientsBody weightWeight lossTherapySignificant differencesHigh rateInfluence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial
Deja MA, Grayburn PA, Sun B, Rao V, She L, Krejca M, Jain AR, Chua Y, Daly R, Senni M, Mokrzycki K, Menicanti L, Oh JK, Michler R, Wróbel K, Lamy A, Velazquez EJ, Lee KL, Jones RH. Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial. Circulation 2012, 125: 2639-2648. PMID: 22553307, PMCID: PMC3776601, DOI: 10.1161/circulationaha.111.072256.Peer-Reviewed Original ResearchConceptsSevere mitral regurgitationMild mitral regurgitationMitral regurgitationMitral valve repairTrace mitral regurgitationMitral surgeryMedical therapyValve repairIschemic Heart Failure (STICH) trialCoronary artery bypassHeart Failure TrialPrimary end pointLeft ventricular dysfunctionCoronary artery diseaseModerate mitral regurgitationBaseline prognostic variablesIschemic mitral regurgitationArtery bypassRandomized patientsVentricular dysfunctionHazard ratioArtery diseaseEjection fractionMedical armSurgical treatment
2011
Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal Of Medicine 2011, 364: 1607-1616. PMID: 21463150, PMCID: PMC3415273, DOI: 10.1056/nejmoa1100356.Peer-Reviewed Original ResearchConceptsMedical therapy groupCardiovascular causesCoronary artery diseaseMedical therapyCABG groupRate of deathArtery diseasePrimary outcomeMajor secondary outcomesCoronary artery bypassPrimary end pointArtery bypass surgeryLeft ventricular dysfunctionTreatment of patientsVentricular dysfunctionBypass surgerySecondary outcomesEjection fractionHeart failureCABGPatientsTherapyEnd pointHospitalizationDeath
2010
Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes
Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, Investigators A. Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. Journal Of The American College Of Cardiology 2010, 56: 77-85. PMID: 20620720, DOI: 10.1016/j.jacc.2010.02.046.Peer-Reviewed Original ResearchConceptsRenin-angiotensin system blockersDiabetic patientsCardiovascular eventsSystem blockersHigh riskPrimary end pointAcute clinical eventsUnexpected adverse eventsPrimary eventACCOMPLISH trialCoronary benefitNondiabetic patientsCardiovascular deathCoronary revascularizationDiabetes groupAdverse eventsBlood pressureHypertension therapyClinical eventsCombination therapyMyocardial infarctionPatientsDiabetesHypertensionEnd point
2008
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal Of Medicine 2008, 359: 2417-2428. PMID: 19052124, DOI: 10.1056/nejmoa0806182.Peer-Reviewed Original ResearchConceptsNonfatal myocardial infarctionCardiovascular eventsNonfatal strokeCardiovascular causesMyocardial infarctionHigh riskEnd pointDihydropyridine calcium channel blockerCurrent U.S. guidelinesComposite of deathDouble-blind trialPrimary end pointPrimary outcome eventSecondary end pointsHigh-risk patientsAbsolute risk reductionRelative risk reductionCalcium channel blockersCombination drug therapySudden cardiac arrestRisk reductionCoronary revascularizationStudy drugAdverse eventsBaseline characteristics
2003
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction